Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-618 | CCR2 | 0.14 | 0.51715 | -0.73 | 0.0032 | miRNATAP | -0.19 | 0.00208 | NA | |
| 2 | hsa-miR-204-5p | CCR5 | -0.54 | 0.03309 | -0.54 | 0.01525 | mirMAP | -0.13 | 0.00204 | NA | |
| 3 | hsa-miR-455-5p | CCR5 | -0.27 | 0.05813 | -0.54 | 0.01525 | miRanda | -0.24 | 0.00165 | NA | |
| 4 | hsa-miR-664a-3p | CCR5 | 0.49 | 0.00073 | -0.54 | 0.01525 | mirMAP | -0.26 | 0.0006 | NA | |
| 5 | hsa-miR-107 | CREB5 | 0.24 | 0.01708 | 0 | 0.99313 | miRNATAP | -0.6 | 0 | NA | |
| 6 | hsa-miR-130b-3p | CREB5 | 0.69 | 0.00011 | 0 | 0.99313 | miRNATAP | -0.28 | 0 | NA | |
| 7 | hsa-miR-17-5p | CREB5 | 0.7 | 2.0E-5 | 0 | 0.99313 | MirTarget; TargetScan; miRNATAP | -0.13 | 0.02492 | NA | |
| 8 | hsa-miR-204-5p | CREB5 | -0.54 | 0.03309 | 0 | 0.99313 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.1 | 0.00867 | NA | |
| 9 | hsa-miR-20a-5p | CREB5 | 0.85 | 0 | 0 | 0.99313 | MirTarget; miRNATAP | -0.15 | 0.01025 | NA | |
| 10 | hsa-miR-32-5p | CREB5 | 0.08 | 0.54898 | 0 | 0.99313 | miRNAWalker2 validate | -0.19 | 0.00954 | NA | |
| 11 | hsa-miR-33a-3p | CREB5 | -0.68 | 1.0E-5 | 0 | 0.99313 | miRNATAP | -0.2 | 0.0018 | NA | |
| 12 | hsa-miR-340-5p | CREB5 | -0 | 0.9685 | 0 | 0.99313 | mirMAP | -0.16 | 0.04787 | NA | |
| 13 | hsa-miR-362-3p | CREB5 | 0.81 | 0 | 0 | 0.99313 | PITA | -0.18 | 0.0109 | NA | |
| 14 | hsa-miR-362-5p | CREB5 | 0.72 | 2.0E-5 | 0 | 0.99313 | PITA | -0.16 | 0.00775 | NA | |
| 15 | hsa-miR-365a-3p | CREB5 | 0.16 | 0.15325 | 0 | 0.99313 | MirTarget | -0.34 | 8.0E-5 | NA | |
| 16 | hsa-miR-532-3p | CREB5 | 0.3 | 0.01463 | 0 | 0.99313 | miRNATAP | -0.32 | 8.0E-5 | NA | |
| 17 | hsa-miR-548b-3p | CREB5 | -0.02 | 0.93082 | 0 | 0.99313 | PITA | -0.21 | 0 | NA | |
| 18 | hsa-miR-576-5p | CREB5 | -0.38 | 0.00471 | 0 | 0.99313 | PITA; mirMAP | -0.24 | 0.00119 | NA | |
| 19 | hsa-miR-616-5p | CREB5 | 0.15 | 0.40284 | 0 | 0.99313 | MirTarget; mirMAP | -0.24 | 1.0E-5 | NA | |
| 20 | hsa-miR-766-3p | CREB5 | 0.2 | 0.25723 | 0 | 0.99313 | MirTarget | -0.14 | 0.01158 | NA | |
| 21 | hsa-miR-27a-3p | CUL1 | -0.37 | 0.00876 | -0.12 | 0.10228 | miRNAWalker2 validate | -0.1 | 4.0E-5 | NA | |
| 22 | hsa-miR-193a-3p | CX3CR1 | -0.12 | 0.30939 | -1.23 | 0 | miRanda | -0.26 | 0.0012 | NA | |
| 23 | hsa-miR-361-5p | CX3CR1 | 0.23 | 0.00962 | -1.23 | 0 | miRanda | -0.24 | 0.02295 | NA | |
| 24 | hsa-miR-362-3p | CX3CR1 | 0.81 | 0 | -1.23 | 0 | miRanda | -0.3 | 1.0E-5 | NA | |
| 25 | hsa-miR-590-5p | CX3CR1 | -0.1 | 0.31003 | -1.23 | 0 | miRanda | -0.25 | 0.00712 | NA | |
| 26 | hsa-miR-224-5p | CXCR2 | 2.67 | 0 | -2.69 | 0 | MirTarget | -0.18 | 3.0E-5 | NA | |
| 27 | hsa-miR-15b-3p | CYLD | 0.24 | 0.09977 | -0.42 | 0 | mirMAP | -0.1 | 0.00045 | NA | |
| 28 | hsa-miR-188-5p | CYLD | 1.12 | 0 | -0.42 | 0 | mirMAP | -0.13 | 0 | NA | |
| 29 | hsa-miR-19a-3p | CYLD | 1.02 | 0 | -0.42 | 0 | miRNATAP | -0.14 | 0 | NA | |
| 30 | hsa-miR-19b-3p | CYLD | 0.6 | 0.00017 | -0.42 | 0 | miRNATAP | -0.17 | 0 | NA | |
| 31 | hsa-miR-301a-3p | CYLD | 0.84 | 0 | -0.42 | 0 | miRNATAP | -0.19 | 0 | NA | |
| 32 | hsa-miR-30b-5p | CYLD | -0.54 | 2.0E-5 | -0.42 | 0 | mirMAP | -0.11 | 0.0008 | NA | |
| 33 | hsa-miR-30d-5p | CYLD | 0.72 | 0 | -0.42 | 0 | mirMAP | -0.17 | 0 | NA | |
| 34 | hsa-miR-362-5p | CYLD | 0.72 | 2.0E-5 | -0.42 | 0 | PITA; TargetScan; miRNATAP | -0.1 | 4.0E-5 | 25449782; 24495516; 26893711 | MicroRNA 362 5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma; We subsequently identified that CYLD was a target gene of miR-362-5p; Furthermore knockdown of CYLD expression partially counteracted the tumor suppressive effects of miR-362-5p inhibitors; Finally we have shown that miR-362-5p acts through CYLD to activate the NF-κB signaling pathway which contributes to HCC progression;Expression of the tumor suppressor CYLD was inhibited by miR-362 in gastric cancer cells; miR-362 levels were inversely correlated with CYLD expression in gastric cancer tissue; MiR-362 downregulated CYLD expression by binding its 3' untranslated region; The results suggest that miR-362 plays an important role in repressing the tumor suppressor CYLD and present a novel mechanism of miRNA-mediated NF-κB activation in gastric cancer;Mechanistic investigations confirmed that the tumor suppressor gene CYLD is a direct target of miR-362-5p; The ectopic expression of miR-362-5p represses CYLD expression whereas miR-362-5p inhibitor treatment induces CYLD protein expression and decreases NF-κB expression in the downstream signaling pathway |
| 35 | hsa-miR-454-3p | CYLD | 0.67 | 0 | -0.42 | 0 | miRNATAP | -0.16 | 0 | 25824771 | MiR 454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression; Bioinformatics analysis further revealed cylindromatosis CYLD a putative tumor suppressor as a potential target of miR-454; Data from luciferase reporter assays showed that miR-454 directly binds to the 3'-untranslated region 3'-UTR of CYLD mRNA and repressed expression at both transcriptional and translational levels; In sum our data provide compelling evidence that miR-454 functions as an onco-miRNA playing a crucial role in the promoting cell proliferation in CRC and its oncogenic effect is mediated chiefly through direct suppression of CYLD expression |
| 36 | hsa-miR-500a-5p | CYLD | 0.8 | 0 | -0.42 | 0 | mirMAP | -0.11 | 0.00017 | NA | |
| 37 | hsa-miR-501-5p | CYLD | 1.15 | 0 | -0.42 | 0 | miRNATAP | -0.12 | 0 | 25917358 | MiR 501 5p regulates CYLD expression and promotes cell proliferation in human hepatocellular carcinoma; Luciferase reporter assays were used to confirm CYLD as a target of miR-501-5p; MiR-501-5p was upregulated in hepatocellular carcinoma specimens and cell lines and directly targeted the 3' untranslated region of CYLD |
| 38 | hsa-miR-590-5p | CYLD | -0.1 | 0.31003 | -0.42 | 0 | miRanda | -0.19 | 0 | NA | |
| 39 | hsa-miR-193a-5p | DDX58 | -0.47 | 1.0E-5 | -0.36 | 0.00103 | MirTarget | -0.14 | 0.00381 | NA | |
| 40 | hsa-miR-25-3p | DDX58 | 0.63 | 0 | -0.36 | 0.00103 | mirMAP | -0.27 | 0 | NA | |
| 41 | hsa-miR-320a | DDX58 | 0.33 | 0.02214 | -0.36 | 0.00103 | miRanda | -0.12 | 0.00131 | NA | |
| 42 | hsa-miR-338-3p | DDX58 | 0.54 | 0.00461 | -0.36 | 0.00103 | miRanda | -0.11 | 5.0E-5 | NA | |
| 43 | hsa-miR-340-5p | DDX58 | -0 | 0.9685 | -0.36 | 0.00103 | MirTarget | -0.12 | 0.00687 | NA | |
| 44 | hsa-miR-362-5p | DDX58 | 0.72 | 2.0E-5 | -0.36 | 0.00103 | miRNATAP | -0.14 | 1.0E-5 | NA | |
| 45 | hsa-miR-126-5p | GFPT1 | -0.43 | 7.0E-5 | 0.1 | 0.2775 | mirMAP | -0.12 | 0.00302 | NA | |
| 46 | hsa-miR-34a-5p | GFPT1 | 1.04 | 0 | 0.1 | 0.2775 | miRNAWalker2 validate | -0.12 | 0.0002 | NA | |
| 47 | hsa-miR-107 | GLS | 0.24 | 0.01708 | 0.64 | 0.00121 | miRanda | -0.4 | 4.0E-5 | NA | |
| 48 | hsa-miR-125b-5p | GLS | -1.36 | 0 | 0.64 | 0.00121 | miRNATAP | -0.34 | 0 | NA | |
| 49 | hsa-miR-23b-3p | GLS | -0.53 | 0 | 0.64 | 0.00121 | miRNATAP | -0.41 | 1.0E-5 | NA | |
| 50 | hsa-miR-32-3p | GLS | 0.22 | 0.20722 | 0.64 | 0.00121 | mirMAP | -0.14 | 0.01754 | NA | |
| 51 | hsa-miR-378c | GLS | -1.54 | 0 | 0.64 | 0.00121 | miRNATAP | -0.35 | 0 | NA | |
| 52 | hsa-miR-455-5p | GLS | -0.27 | 0.05813 | 0.64 | 0.00121 | miRanda | -0.21 | 0.00214 | NA | |
| 53 | hsa-miR-486-5p | GLS | -1.78 | 0 | 0.64 | 0.00121 | miRanda | -0.19 | 0 | NA | |
| 54 | hsa-miR-140-5p | GNAS | -0.22 | 0.01407 | 0.11 | 0.34864 | miRanda | -0.28 | 0 | NA | |
| 55 | hsa-miR-590-3p | GNAS | -0.47 | 2.0E-5 | 0.11 | 0.34864 | miRanda | -0.12 | 0.01722 | NA | |
| 56 | hsa-miR-107 | HIF1A | 0.24 | 0.01708 | -0.37 | 0.0111 | miRNAWalker2 validate; miRTarBase; miRanda | -0.44 | 0 | NA | |
| 57 | hsa-miR-17-5p | HIF1A | 0.7 | 2.0E-5 | -0.37 | 0.0111 | miRTarBase; MirTarget; TargetScan | -0.21 | 0 | NA | |
| 58 | hsa-miR-20a-5p | HIF1A | 0.85 | 0 | -0.37 | 0.0111 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.25 | 0 | 22901144 | Correlation analysis showed that the key miRNAs miR-20a and miR-20b negatively correlated with the target proteins VEGF-A and HIF-1alpha |
| 59 | hsa-miR-33a-5p | HIF1A | -0.77 | 1.0E-5 | -0.37 | 0.0111 | miRNAWalker2 validate | -0.11 | 0.0073 | NA | |
| 60 | hsa-miR-616-5p | HIF1A | 0.15 | 0.40284 | -0.37 | 0.0111 | MirTarget | -0.12 | 0.00144 | NA | |
| 61 | hsa-miR-660-5p | HIF1A | 0.99 | 0 | -0.37 | 0.0111 | MirTarget | -0.25 | 0 | NA | |
| 62 | hsa-miR-93-5p | HIF1A | 1.4 | 0 | -0.37 | 0.0111 | MirTarget | -0.17 | 0.00043 | NA | |
| 63 | hsa-miR-361-5p | IFNAR1 | 0.23 | 0.00962 | -0.79 | 0 | miRanda | -0.16 | 0.00059 | NA | |
| 64 | hsa-miR-3913-5p | IFNAR1 | 0.25 | 0.0628 | -0.79 | 0 | mirMAP | -0.13 | 4.0E-5 | NA | |
| 65 | hsa-miR-181b-5p | IFNGR1 | 0.49 | 0.00105 | -0.36 | 0.01168 | miRNAWalker2 validate | -0.27 | 0 | NA | |
| 66 | hsa-miR-362-3p | IFNGR1 | 0.81 | 0 | -0.36 | 0.01168 | miRanda | -0.13 | 0.00937 | NA | |
| 67 | hsa-miR-501-5p | JUN | 1.15 | 0 | -1.6 | 0 | MirTarget; PITA; miRNATAP | -0.2 | 0 | NA | |
| 68 | hsa-miR-92a-3p | JUN | 0.21 | 0.13429 | -1.6 | 0 | miRNATAP | -0.22 | 0.00019 | NA | |
| 69 | hsa-miR-93-5p | JUN | 1.4 | 0 | -1.6 | 0 | miRNAWalker2 validate | -0.35 | 0 | NA | |
| 70 | hsa-let-7c-5p | MGAT4A | -1.71 | 0 | 0.1 | 0.34719 | MirTarget | -0.14 | 0 | NA | |
| 71 | hsa-miR-101-3p | MGAT4A | -1.48 | 0 | 0.1 | 0.34719 | MirTarget | -0.2 | 0 | NA | |
| 72 | hsa-miR-107 | MGAT4A | 0.24 | 0.01708 | 0.1 | 0.34719 | miRanda | -0.15 | 0.00679 | NA | |
| 73 | hsa-miR-125b-5p | MGAT4A | -1.36 | 0 | 0.1 | 0.34719 | miRNATAP | -0.21 | 0 | NA | |
| 74 | hsa-miR-126-5p | MGAT4A | -0.43 | 7.0E-5 | 0.1 | 0.34719 | MirTarget; mirMAP | -0.1 | 0.04249 | NA | |
| 75 | hsa-miR-139-5p | MGAT4A | -2.11 | 0 | 0.1 | 0.34719 | MirTarget; PITA; miRanda; miRNATAP | -0.14 | 0 | NA | |
| 76 | hsa-miR-148a-3p | MGAT4A | -0.75 | 0 | 0.1 | 0.34719 | MirTarget; miRNATAP | -0.19 | 0 | NA | |
| 77 | hsa-miR-148a-5p | MGAT4A | -0.77 | 0 | 0.1 | 0.34719 | mirMAP | -0.17 | 0 | NA | |
| 78 | hsa-miR-15a-5p | MGAT4A | 0.35 | 0.00077 | 0.1 | 0.34719 | MirTarget; miRNATAP | -0.1 | 0.04625 | NA | |
| 79 | hsa-miR-194-5p | MGAT4A | -0.29 | 0.09961 | 0.1 | 0.34719 | miRNATAP | -0.1 | 0.00056 | NA | |
| 80 | hsa-miR-23b-3p | MGAT4A | -0.53 | 0 | 0.1 | 0.34719 | mirMAP | -0.17 | 0.00072 | NA | |
| 81 | hsa-miR-30b-3p | MGAT4A | -0.44 | 0.00095 | 0.1 | 0.34719 | MirTarget | -0.12 | 0.00311 | NA | |
| 82 | hsa-miR-30d-3p | MGAT4A | -0.12 | 0.32955 | 0.1 | 0.34719 | mirMAP | -0.11 | 0.01333 | NA | |
| 83 | hsa-miR-34a-5p | MGAT4A | 1.04 | 0 | 0.1 | 0.34719 | MirTarget; miRNATAP | -0.18 | 0 | NA | |
| 84 | hsa-miR-374a-5p | MGAT4A | 0.02 | 0.86978 | 0.1 | 0.34719 | MirTarget | -0.12 | 0.02219 | NA | |
| 85 | hsa-miR-374b-5p | MGAT4A | -0.31 | 0.00301 | 0.1 | 0.34719 | MirTarget; miRNATAP | -0.12 | 0.01885 | NA | |
| 86 | hsa-miR-664a-3p | MGAT4A | 0.49 | 0.00073 | 0.1 | 0.34719 | mirMAP | -0.13 | 0.00058 | NA | |
| 87 | hsa-miR-16-5p | PDCD4 | -0.4 | 0.0001 | -0.1 | 0.34566 | miRNAWalker2 validate; miRNATAP | -0.15 | 0.00219 | NA | |
| 88 | hsa-miR-186-5p | PDCD4 | -0.06 | 0.53529 | -0.1 | 0.34566 | MirTarget; mirMAP | -0.11 | 0.02946 | NA | |
| 89 | hsa-miR-193b-5p | PDCD4 | -0.75 | 0 | -0.1 | 0.34566 | MirTarget | -0.12 | 6.0E-5 | NA | |
| 90 | hsa-miR-21-5p | PDCD4 | 1.51 | 0 | -0.1 | 0.34566 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.13 | 0.0003 | 22322403; 23604124; 20978511; 25973032; 25575817; 25316501; 22072622; 22267128; 19836969; 22212233; 25520758; 19682430; 23272133; 25477028; 26252635; 25994220; 25991676; 22747440; 23827854; 23824073; 24865582; 24902663; 24888238; 24149370; 17991735; 22689922; 27355932; 19308091; 24331411; 26169933; 22547075; 20372781; 23558936; 23201752; 20815812; 17968323; 25310697; 21842656; 23567619; 20581857; 23888942; 23548551; 19013014; 21685938; 26142886; 24472409; 26418978; 24659669; 22086602; 26212010; 25543482; 25543261; 23904372; 27725205; 23564788; 25400316; 26150475; 21546206; 19509156; 27035745; 23052036; 22353043; 19633292; 25566594; 21412018; 19276261; 21330826; 26864640; 22335905; 21636706 | miR 21 promotes migration and invasion by the miR 21 PDCD4 AP 1 feedback loop in human hepatocellular carcinoma; The expression level of miR-21 was inversely correlated with the protein expression level of a previously identified target gene programmed cell death 4 PDCD4;HBx mediated miR 21 upregulation represses tumor suppressor function of PDCD4 in hepatocellular carcinoma; HBx downregulates PDCD4 expression at least partially through miR-21; Taken together this study reported for the first time that HBx downregulates PDCD4 and upregulates miR-21 expression; The deregulation of PDCD4 by HBx through miR-21 represents a potential novel mechanism of the downregulation of PDCD4 in HBV-related HCC and provides new insights into HCC development;Transfection of anti-miR-21 rendered HCC cells sensitive to IFN-α/5-FU and such sensitivity was weakened by transfection of siRNAs of target molecules PETN and PDCD4 miR-21 expression in clinical HCC specimens was significantly associated with the clinical response to the IFN-α/5-FU combination therapy and survival rate;PDCD4 and PTEN expression was decreased gradually after tumor induction and negatively correlated with miR-21 expression; Our in vivo experiments further confirmed that miR-21 plays an important role in promoting the occurrence and development of HCC by regulating PDCD4 and PTEN;We identified miR-21 was directly downregulated by RBP2 and found that miR-21 downregulated PDCD4 expression in leukemia cells;MTCs were consistently associated with miR-21 up-regulation P < .0016 and featured significant PDCD4 nuclear down-regulation; An inverse correlation emerged between miR-21 overexpression and PDCD4 down-regulation P = .0013; This study showed in MTCs that miR-21 regulates PDCD4 expression and also that the miR-21/PDCD4 pathway correlates with clinicopathological variables and prognosis;Although microRNA-21 miR-21 is emerging as an oncogene and has been shown to target several tumor suppressor genes including programmed cell death 4 PDCD4 its precise mechanism of action on cancer stem cells CSCs is unclear; Herein we report that FOLFOX-resistant HCT-116 and HT-29 cells that are enriched in CSCs show a 3- to 7-fold upregulation of pre- and mature miR-21 and downregulation of PDCD4; Likewise overexpression of miR-21 in HCT-116 cells achieved through stable transfection led to the downregulation of PDCD4 and transforming growth factor beta receptor 2 TGFβR2;Prognostic significance of PDCD4 expression and association with microRNA 21 in each Dukes' stage of colorectal cancer patients; Furthermore relationships between the PDCD4 mRNA and microRNA-21 miR-21 were evaluated; The PDCD4 mRNA was investigated by the quantitative real-time RT-PCR method and miR-21 was examined by TaqMan microRNA assays; Significant inverse correlations were demonstrated between PDCD4 and miR-21;This short review will focus on our recent finding that the microRNA miR-21 posttranscriptionally regulates Pdcd4 as well as invasion intravasation and metastasis;PDCD4 expression inversely correlated with miR 21 levels in gastric cancers;MicroRNA 21 Down regulates Rb1 Expression by Targeting PDCD4 in Retinoblastoma; MicroRNA-21 miR-21 possesses the oncogenic potential to target several tumor suppressor genes including PDCD4 and regulates tumor progression and metastasis; However the mechanism of how miR-21 regulates PDCD4 is poorly understood in RB; Using the TargetScan program we identified a list of potential target genes of these miRNAs of which PDCD4 is one the targets of miR-21; In this study we focused on the regulatory mechanism of miR-21 on PDCD4 in RB; We demonstrated an inverse correlation between miR-21 and PDCD4 expression in Weri-Rb1 and Y79 cells; These data suggest that miR-21 down-regulates Rb1 by targeting PDCD4 tumor suppressor;MicroRNA 21 promotes cell proliferation and down regulates the expression of programmed cell death 4 PDCD4 in HeLa cervical carcinoma cells; In this study we found that the inhibition of miR-21 in HeLa cervical cancer cells caused profound suppression of cell proliferation and up-regulated the expression of the tumor suppressor gene PDCD4;Additionally resveratrol increased the expression of tumor suppressors PDCD4 and maspin which are negatively regulated by miR-21; Short interfering si RNA against PDCD4 attenuated resveratrol's effect on prostate cancer cells and similar effects were observed following over expression of miR-21 with pre-miR-21 oligonucleotides; MiR-21 expression in these cells appeared to be dependent on Akt as LY294002 reduced the levels of miR-21 along with a concurrent increase in PDCD4 expression; These tumor- and metastatic-suppressive effects of resveratrol were associated with reduced miR-21 and pAkt and elevated PDCD4 levels;The expression of miR-21 and PDCD4 mRNA in transfected cells was quantified by real-time polymerase chain reaction and the expression of PDCD4 protein by Western blot; Cell proliferation apoptosis migration and invasion assays were performed to determine the biological effects of miR-21 expression and PDCD4 inhibition; Co-transfection of miR-21-sponge with PDCD4 siRNA upregulated miR-21 expression in these cells; PDCD4 mRNA and protein levels were increased 2.14-fold and 2.16-fold respectively following inhibition of miR-21 expression; Depletion of PDCD4 by siRNA transfection reversed the reduction of cell proliferation migration and invasion induced by inhibition of miR-21 in A549 cells; It indicates that miR-21 is highly expressed in patients with NSCLC and inhibition of miR-21 expression reduces proliferation migration and invasion of A549 cells by upregulating PDCD4 expression; Modulation of miR-21 or PDCD4 expression may provide a potentially novel therapeutic approach for NSCLC;IL 6 Inhibits the Targeted Modulation of PDCD4 by miR 21 in Prostate Cancer; In this study we evaluated the role of IL-6 in PDCD4 gene expression and how the microRNA miR-21 regulates this process in prostate cancer cell lines PC-3 and LNCaP; The expression of PDCD4 was inhibited by IL-6 but this effect was weakened in cell lines with low expression of miR-21; These findings support the feasibility of future efforts for diagnosis and gene therapy for prostate cancer that are based on IL-6 miR-21 and PDCD4;Furthermore the absence of miR-21 increased the expression of its target gene PDCD4 and subsequently modulated nuclear factor NF-κB activation;In this study using reverse phase protein arrays RPPAs we assessed MPS1 mediated cell signaling pathways and demonstrated that inhibiting MPS1 could upregulate the expression of the tumor suppressor PDCD4 and MSH2 genes by down regulating micro RNA-21 miR-21; We also show the prognostic effect of miR21 PDCD4 and MSH2 levels to patient survival across different GBM molecular subtypes;We also analyzed the immunohistochemical expression of PDCD4 an miR-21 gene target; PDCD4 expression was significantly downregulated in MTC samples consistent with miR-21 upregulation;Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA 21 mediated programmed cell death 4 PDCD4 expression; Further AR inhibition also increased PDCD4 a putative target of miR-21 in human colon cancer cells; Collectively these results indicate that AR inhibition prevents growth factor-induced colon cancer growth by down-regulating miR-21 expression and increasing PDCD4 levels through the reactive oxygen species ROS/AMPK/mTOR/AP1/4E-BP1 pathway;Berberine could inhibit miR-21 expression and function in ovarian cancer as shown by an enhancement of its target PDCD4 an important tumor suppressor in ovarian cancer;Overexpression of miR-21 in cisplatin sensitive cells decreased PDCD4 levels and increased cell proliferation;MicroRNA 21 miR 21 post transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation proliferation and metastasis in renal cell carcinoma; MiR-21 induces neoplastic transformation cell proliferation and metastasis and downregulates programmed cell death4 PDCD4 in some cancers; The aim of this study was to investigate the roles and interactions of PDCD4 and miR-21 in human renal cell carcinoma RCC; The expression levels of PDCD4 protein and mRNA and miR-21 were examined by Western blot analysis and by qRT-PCR and luciferase reporter assays; MiR-21 not only promoted cancer cell hyperplasia and contributed to tumor cell transformation and metastasis but also post-transcriptionally downregulated PDCD4 protein expression; PDCD4 and miR-21 expression levels potentially play an important role in renal cell cancer;Programmed cell death 4 PDCD4 is a tumor suppressor gene whose expression is directly controlled by microRNA-21 miR-21; This PDCD4 and miR-21 inverse expression was also noted in cells and exosomes from OSC peritoneal effusions compared with nonneoplastic effusions; PDCD4 and miR-21 are involved in OSC oncogenesis;Finally in a subgroup of tumor specimens ROC curve analysis performed on quantitative PCR data sets for miR-21 ITGβ4 and PDCD4 shows that the combination of high miR-21 with low ITGβ4 and PDCD4 expression is able to predict presence of metastasis; In conclusion miR-21 is a key player in oncogenic EMT its overexpression is controlled by the cooperation of genetic and epigenetic alterations and its levels along with ITGβ4 and PDCD4 expression could be exploited as a prognostic tool for CRC metastasis;Programmed cell death 4 PDCD4 is an important functional target of the microRNA miR 21 in breast cancer cells;In ZD esophagus and tongue oncogenic miR-31 and miR-21 overexpression was accompanied by down-regulation of their respective tumor-suppressor targets PPP2R2A and PDCD4;Due to inhibition of miR-21 expression of the programed cell death 4 PDCD4 gene was promoted in tumors resulting in the induction of apoptosis of tumor cells;We also demonstrated that BMP-6-induced downregulation of miR-21 modified the activity of PDCD4 3'UTR and inhibited MDA-MB-231 cell invasion;The level of miR-21 was reversely correlated with the expression of PTEN and PDCD4 and positive correlated with PI3K/Akt pathway; miR-21 is involved in acquired resistance of EGFR-TKI in NSCLC which is mediated by down-regulating PTEN and PDCD4 and activating PI3K/Akt pathway;The results indicated that the miR-21 inhibition could induce the cell cycle arrest in G1 phase upregulate the expression of Programmed Cell Death Protein 4 PDCD4 and thus active the caspase-3 apoptosis pathway;Induction of miR-21 may enable cancer cells to elude DNA damage-induced apoptosis and enhance the metastatic potential of breast cancer cells through repressing expression of PTEN and PDCD4;Clinicopathological and prognostic significance of PDCD4 and microRNA 21 in human gastric cancer; Recent studies have demonstrated that the novel tumor suppressor protein programmed cell death 4 PDCD4 is downregulated in several human solid cancer types and is suppressed by microRNA-21 miR-21; The objectives of this study were: i to establish the clinicopathological and prognostic significance of PDCD4 mRNA and ii to elucidate any correlation between PDCD4 mRNA and miR-21 in gastric cancer; We also performed an association study comparing PDCD4 mRNA and miR-21 in eight cell lines and 49 gastric cancers; An inverse correlation between PDCD4 mRNA and miR-21 was found in gastric cancer; Furthermore our findings suggest that PDCD4 mRNA is negatively regulated by miR-21 in gastric cancer and may serve as a target for effective therapies;Furthermore miR-21 mimic or inhibitor significantly reduced or increased the expression of PDCD4 and TPM1; MiR-21 is overexpressed in RCC tissue and modulates the growth apoptosis and cell cycle progression of RCC cells and regulates the expression of PDCD4 and TPM1;Moreover we demonstrate that oligonucleotide-mediated miR-21 silencing in U87 human GBM cells resulted in increased levels of the tumor suppressors PTEN and PDCD4 caspase 3/7 activation and decreased tumor cell proliferation;Curcumin treatment reduced miR-21 promoter activity and expression in a dose-dependent manner by inhibiting AP-1 binding to the promoter and induced the expression of the tumour suppressor Pdcd4 programmed cell death protein 4 which is a target of miR-21; Taken together this is the first paper to show that curcumin inhibits the transcriptional regulation of miR-21 via AP-1 suppresses cell proliferation tumour growth invasion and in vivo metastasis and stabilizes the expression of the tumour suppressor Pdcd4 in colorectal cancer;MicroRNA 21 miR 21 post transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion intravasation and metastasis in colorectal cancer; This is the first study to show that Pdcd4 is negatively regulated by miR-21;Inflammation and MiR 21 pathways functionally interact to downregulate PDCD4 in colorectal cancer; These findings indicate that miR-21 is a component of the COX-2 inflammation pathway and that this pathway promotes worsening of disease stage in colorectal cancer by inducing accumulation of PGE2 and increasing expression of miR-21 with consequent downregulation of the tumour suppressor gene PDCD4;The expression of miR-21 PTEN and PDCD4 were determined by Real-time PCR; Glossy ganoderma spore oil down-regulated the expression of miR-21 and up-regulated the expression of PTEN and PDCD4 significantly;Interestingly NVP-LDE-225 induced PDCD4 and apoptosis and inhibited cell viability by suppressing miR-21;PDCD4 a direct target gene of miR-21 could mediate chemoresistance to docetaxel in PC3 cells;Oxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR 21; The expression of miR-21 and PDCD4 was highly correlated with the degree of differentiation tumor staging local lymphatic node metastasis and remote metastasis; In addition the relative expression of PDCD4 was negatively correlated with miR-21; Thus we conclude that ROS promotes gastric carcinogenesis via upregulating miR-21 expression which in turn down-regulates the expression of PDCD4 in gastric cancer cells;Moreover knockdown of miR-21 increased PDCD4 and PTEN expression at the protein level but not at the mRNA level;MicroRNA 21 down regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G; Expression of PDCD4 protein correlates inversely with expression of miR-21 in a number of human glioblastoma cell lines such as T98G A172 U87 and U251; Inhibition of miR-21 increases endogenous levels of PDCD4 in cell line T98G and over-expression miR-21 inhibits PDCD4-dependent apoptosis;Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events abrogates miR-21 production and increases PDCD4 expression;Programmed cell death 4 PDCD4 is critical in mediating apoptosis in GBM and is downregulated by miR-21 which may mediate the resistance of glioblastoma cells against chemotherapy or radiation via its target genes PDCD4; This review will focus on the roles of miRNAs family members particularly miR-21 and its target gene PDCD4 in tumors like glioblastoma and new targeting strategies as examples some new targeting therapeutic methods and molecular mechanisms of signal pathways in glioblastoma therapeutics to give the reader the current trends of approach to target regulation of these miRNA and genes for future glioma therapies;Using Western blot analysis miR-21 knockdown enhanced the expression of tumor suppressor PDCD4 and attenuated apoptosis inhibitor c-IAP2;METHODS 3-45-dimethylthiazol-2-yl-25-diphenyltetrazolium bromide MTT assay was used to determine the effect of 5-FU on the viability of RKO cells with knockout of miR-21 or high expression of PDCD4;The protein levels of miR-21 targets PTEN and PDCD4 were estimated; In the control experiment miR-21 mimic significantly inhibited the expression of PTEN and PDCD4 proteins in the two gastric cell lines leading to an increase in cell invasion and migration; miR-21 is overexpressed in gastric cancer and its aberrant expression may have important role in gastric cancer growth and dissemination by modulating the expression of the tumor suppressors PTEN and PDCD4 as well as by modulating the pathways involved in mediating cell growth migration invasion and apoptosis;The effects were accompanied by up-regulation of tumor suppressor PDCD4 a known miR-21 target; as well as up-regulation of cofilin and profilin two key proteins involved in actin polymerization and cytoskeleton maintenance as a consequence of miR-182 down-regulation;Increased levels of miR-21 in turn downregulate the expression of the metastasis-suppressor protein programmed cell death 4 PDCD4 a validated miR-21 target;Moreover knockdown of miR-21 increased the expressions of PDCD4 and PTEN at the protein level but not at the mRNA level;In this study we analyzed the expression of miR-21 and of its target PDCD4 Programmed Cell Death 4 during normal hematopoietic differentiation and in AMLs;MiR 21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2; In addition miR-21 knockdown increased the expression of endogenous PDCD4 and hMSH2 which contributed to the apoptosis and G2 arrest of T98G cells; The findings suggested that miR-21 may mediate the resistance of glioblastoma cells against radiation via its target genes PDCD4 and hMSH2;The results showed that upon exposure to mUA miR-21 expression was decreased and the expression of PTEN and Pdcd4 protein was elevated;The expression of programmed cell death-4 PDCD4 was increased by I3C and reduced by miR-21 transfection; Such enhanced chemosensitivity might be explained by the increased expression of PDCD4 which is a downstream target which miR-21 negatively regulates;It has been reported that miR-21 was upregulated in most malignant cancers the proposed mechanism of which was through suppressing expression of programmed cell death 4 PDCD4; In present study it is firstly reported that miR-21 was upregulated in Kazakh's ESCC and that miR-21 played a negative role in regulating PDCD4 using in situ hybridization ISH and luciferase reporter approach;To measure levels of microRNA miR-21 and its target gene programmed cell death 4 PDCD4 in samples of human cutaneous malignant melanoma and normal non-malignant control skin; Relative levels of miR-21 and PDCD4 mRNA were measured using a quantitative real-time reverse transcription-polymerase chain reaction; Compared with normal skin samples the relative level of miR-21 was significantly higher and the relative level of PDCD4 mRNA was significantly lower in the melanoma specimens; A significant negative correlation between PDCD4 mRNA and miR-21 was demonstrated in malignant melanoma r = -0.602; Elevated miR-21 and reduced PDCD4 mRNA levels were both significantly correlated with increased tumour size a higher Clark classification level and the presence of lymph node metastases in malignant melanoma; These findings suggest that miR-21 and PDCD4 might be potential biomarkers for malignant melanoma and might provide treatment targets in the future;MicroRNA 21 and PDCD4 expression in colorectal cancer; Studies have shown that miR-21 exerts its oncogenic activity by targeting the PDCD4 tumour suppressor 3'-UTR; The purpose of this study was to delineate the interaction between PDCD4 and its oncogenic modulator miR-21 in colorectal cancer; A cohort of 48 colorectal tumours 61 normal tissues and 7 polyps were profiled for miR-21 and PDCD4 gene expression; A significant inverse relationship between miR-21 and PDCD4 gene expression p < 0.001 was identified by RT-qPCR; In addition significant reduction of PDCD4 p < 0.001 expression and reciprocal upregulation of miR-21 p = 0.005 in a progressive manner from tumour-polyp-normal mucosae was identified; This study demonstrates the inverse relationship between miR-21 and PDCD4 thus suggesting that miR-21 post-transcriptionally modulates PDCD4 via mRNA degradation;Expression patterns of miR-21 RNA and its target tumor suppressor protein PDCD4 were mutually exclusive;Exosome shuttling microRNA 21 promotes cell migration and invasion targeting PDCD4 in esophageal cancer;Fenhexamid and fludioxonil stimulated miR-21 expression in a concentration-dependent manner and reduced the expression of miR-21 target Pdcd4 protein; Antisense to miR-21 blocked the increase in Pdcd4 protein by fenhexamid and fludioxonil;The expression of programmed cell death 4 PDCD4 which is a miR-21 targeting apoptotic gene has also been enhanced by UA; And over-expression of miR-21 in U251 cells abolished the enhancement of PDCD4 protein by UA;This process leads to microRNA-21 miR-21 production and a tumor suppressor protein e.g PDCD4 program cell death 4 reduction; Transfection of MCF-7 cells with PKCepsilon or Nanog-specific small interfering RNAs effectively blocks HA-mediated PKCepsilon-Nanog signaling events abrogates miR-21 production and increases PDCD4 expression/eIF4A binding;Through dual-luciferase method it was verified that PDCD4 and PDCD10 were real target genes of miR-21 and miR-200c respectively;miR-21 and miR-155 expression was assessed in tumor tissue and in adjacent normal tissue of 156 CRC patients by TaqMan MicroRNA assays and PDCD4 and TP53INP1 mRNA levels were measured by quantitative real-time reverse transcriptase PCR RT-PCR; Significant inverse correlations were demonstrated between miR-21 and PDCD4 mRNA and miR-155 and TP53INP1 mRNA;The aim of this study was a to determine a role of microRNA-21 in esophageal squamous cell carcinoma and b to elucidate the regulation of the programmed cell death 4 PDCD4 gene by microRNA-21; In addition the regulation of PDCD4 by microRNA-21 was elucidated to identify the mechanisms of this regulation; The PDCD4 protein levels in esophageal squamous cell carcinoma cells have an inverse correlation with microRNA-21 expression; MicroRNA-21 targets PDCD4 at the posttranscriptional level and regulates cell proliferation and invasion in esophageal squamous cell carcinoma;Maspin Pdcd4 and miR-21 expressions were evaluated by a real-time polymerase chain reaction in 20 endometrial cancer and 10 normal endometrium samples; Comparison between IA and more advanced International Federation of Gynecology and Obstetrics stages of endometrial cancer in regard to expression levels of maspin Pdcd4 and miR-21 did not reveal any significant differences;MicroRNA 21 induces 5 fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4; The proresistance effects of miR-21 were attributed to the attenuated expression of tumor suppressor genes including PTEN and PDCD4;Sequence prediction and gene expression regulation assays showed that miR-21 could reversely regulate the expression of PDCD4 P < 0.01; Suppression of miR-21 expression is associated with an elevation of Pdcd4 resulting in a significant reduction of proliferation and the apoptosis rate 2.6% was increased to 10.9%; Moreover the anti-proliferation and pro-apoptotic effect by miR-21 suppression could be reversed by PDCD4 knock down;Downregulation of Pdcd4 by mir 21 facilitates glioblastoma proliferation in vivo; We demonstrate that downregulation of mir-21 in glioblastoma-derived cell lines results in increased expression of its target programmed cell death 4 Pdcd4 a known tumor-suppressor gene; In addition our data indicate that either downregulation of mir-21 or overexpression of its target Pdcd4 in glioblastoma-derived cell lines leads to decreased proliferation increased apoptosis and decreased colony formation in soft agar; Using a glioblastoma xenograft model in immune-deficient nude mice we observe that glioblastoma-derived cell lines in which mir-21 levels are downregulated or Pdcd4 is over-expressed exhibit decreased tumor formation and growth; These critical in vivo findings demonstrate an important functional linkage between mir-21 and Pdcd4 and further elucidate the molecular mechanisms by which the known high level of mir-21 expression in glioblastoma can attribute to tumorigenesis--namely inhibition of Pdcd4 and its tumor-suppressive functions |
| 91 | hsa-miR-125a-3p | PER1 | -0.84 | 4.0E-5 | -1.03 | 0 | miRanda | -0.11 | 0.00481 | NA | |
| 92 | hsa-miR-17-5p | PER1 | 0.7 | 2.0E-5 | -1.03 | 0 | miRNAWalker2 validate; TargetScan | -0.22 | 0 | NA | |
| 93 | hsa-miR-423-5p | PER1 | 0.7 | 0 | -1.03 | 0 | PITA; miRNATAP | -0.41 | 0 | NA | |
| 94 | hsa-miR-130b-3p | PFKFB3 | 0.69 | 0.00011 | -1.31 | 0 | miRNATAP | -0.21 | 0.00217 | NA | |
| 95 | hsa-miR-17-5p | PFKFB3 | 0.7 | 2.0E-5 | -1.31 | 0 | MirTarget; TargetScan | -0.21 | 0.00344 | NA | |
| 96 | hsa-miR-192-3p | PFKFB3 | -0.64 | 0.00027 | -1.31 | 0 | mirMAP | -0.5 | 0 | NA | |
| 97 | hsa-miR-19a-3p | PFKFB3 | 1.02 | 0 | -1.31 | 0 | miRNATAP | -0.16 | 0.00774 | NA | |
| 98 | hsa-miR-19b-1-5p | PFKFB3 | -0.28 | 0.07831 | -1.31 | 0 | mirMAP | -0.16 | 0.03889 | NA | |
| 99 | hsa-miR-19b-3p | PFKFB3 | 0.6 | 0.00017 | -1.31 | 0 | miRNATAP | -0.2 | 0.00704 | NA | |
| 100 | hsa-miR-204-5p | PFKFB3 | -0.54 | 0.03309 | -1.31 | 0 | mirMAP | -0.2 | 2.0E-5 | NA | |
| 101 | hsa-miR-20a-5p | PFKFB3 | 0.85 | 0 | -1.31 | 0 | MirTarget | -0.27 | 9.0E-5 | NA | |
| 102 | hsa-miR-616-5p | PFKFB3 | 0.15 | 0.40284 | -1.31 | 0 | mirMAP | -0.32 | 0 | NA | |
| 103 | hsa-miR-93-5p | PFKFB3 | 1.4 | 0 | -1.31 | 0 | MirTarget | -0.27 | 0.00149 | NA | |
| 104 | hsa-miR-199b-5p | PIGV | -0.45 | 0.25461 | -1.07 | 0 | miRanda | -0.11 | 0 | NA | |
| 105 | hsa-miR-335-3p | PIGV | -0.28 | 0.10663 | -1.07 | 0 | MirTarget | -0.16 | 0 | NA | |
| 106 | hsa-miR-542-3p | RIPK2 | -1.31 | 0 | 0.45 | 0.0013 | miRanda | -0.1 | 0.03373 | NA | |
| 107 | hsa-miR-103a-3p | RNASEL | 0.77 | 0 | -0.3 | 0.08846 | MirTarget | -0.44 | 0 | NA | |
| 108 | hsa-miR-106a-5p | RNASEL | -0.46 | 0.00972 | -0.3 | 0.08846 | MirTarget | -0.2 | 3.0E-5 | NA | |
| 109 | hsa-miR-106b-5p | RNASEL | 0.65 | 0 | -0.3 | 0.08846 | MirTarget | -0.56 | 0 | NA | |
| 110 | hsa-miR-107 | RNASEL | 0.24 | 0.01708 | -0.3 | 0.08846 | MirTarget; miRanda | -0.34 | 5.0E-5 | NA | |
| 111 | hsa-miR-148b-3p | RNASEL | 0.27 | 0.00185 | -0.3 | 0.08846 | MirTarget | -0.5 | 0 | NA | |
| 112 | hsa-miR-17-5p | RNASEL | 0.7 | 2.0E-5 | -0.3 | 0.08846 | MirTarget | -0.47 | 0 | NA | |
| 113 | hsa-miR-193a-3p | RNASEL | -0.12 | 0.30939 | -0.3 | 0.08846 | miRanda | -0.36 | 0 | NA | |
| 114 | hsa-miR-200b-3p | RNASEL | -1.29 | 0.00027 | -0.3 | 0.08846 | MirTarget | -0.13 | 0 | NA | |
| 115 | hsa-miR-200c-3p | RNASEL | -0.1 | 0.71696 | -0.3 | 0.08846 | MirTarget | -0.12 | 3.0E-5 | NA | |
| 116 | hsa-miR-20a-5p | RNASEL | 0.85 | 0 | -0.3 | 0.08846 | MirTarget | -0.38 | 0 | NA | |
| 117 | hsa-miR-320a | RNASEL | 0.33 | 0.02214 | -0.3 | 0.08846 | miRanda | -0.25 | 2.0E-5 | NA | |
| 118 | hsa-miR-320b | RNASEL | 0.09 | 0.60798 | -0.3 | 0.08846 | miRanda | -0.18 | 0.00017 | NA | |
| 119 | hsa-miR-324-5p | RNASEL | 0.37 | 0.00592 | -0.3 | 0.08846 | miRanda | -0.36 | 0 | NA | |
| 120 | hsa-miR-330-5p | RNASEL | 0.44 | 0.00533 | -0.3 | 0.08846 | miRanda | -0.11 | 0.04933 | NA | |
| 121 | hsa-miR-335-5p | RNASEL | -1.61 | 0 | -0.3 | 0.08846 | miRNAWalker2 validate | -0.16 | 0.00036 | NA | |
| 122 | hsa-miR-338-3p | RNASEL | 0.54 | 0.00461 | -0.3 | 0.08846 | miRanda | -0.23 | 0 | NA | |
| 123 | hsa-miR-338-5p | RNASEL | -0.22 | 0.25239 | -0.3 | 0.08846 | mirMAP | -0.22 | 0 | NA | |
| 124 | hsa-miR-375 | RNASEL | -1.93 | 0 | -0.3 | 0.08846 | miRanda | -0.16 | 0 | NA | |
| 125 | hsa-miR-421 | RNASEL | 0.94 | 0 | -0.3 | 0.08846 | miRanda | -0.19 | 0.0001 | NA | |
| 126 | hsa-miR-429 | RNASEL | -1.4 | 7.0E-5 | -0.3 | 0.08846 | MirTarget; miRanda | -0.14 | 0 | NA | |
| 127 | hsa-miR-589-3p | RNASEL | 1.17 | 0 | -0.3 | 0.08846 | mirMAP | -0.11 | 0.02283 | NA | |
| 128 | hsa-miR-590-5p | RNASEL | -0.1 | 0.31003 | -0.3 | 0.08846 | miRanda | -0.18 | 0.03658 | NA | |
| 129 | hsa-miR-93-5p | RNASEL | 1.4 | 0 | -0.3 | 0.08846 | MirTarget | -0.33 | 0 | NA | |
| 130 | hsa-miR-106a-5p | SQSTM1 | -0.46 | 0.00972 | 0.81 | 0 | miRNATAP | -0.13 | 0.00606 | NA | |
| 131 | hsa-miR-139-5p | SQSTM1 | -2.11 | 0 | 0.81 | 0 | miRanda | -0.18 | 0 | NA | |
| 132 | hsa-miR-200a-3p | SQSTM1 | -1.5 | 3.0E-5 | 0.81 | 0 | mirMAP | -0.13 | 0 | NA | |
| 133 | hsa-miR-28-5p | SQSTM1 | -0.43 | 0 | 0.81 | 0 | miRanda | -0.23 | 0.01223 | NA | |
| 134 | hsa-miR-335-5p | SQSTM1 | -1.61 | 0 | 0.81 | 0 | miRNAWalker2 validate | -0.32 | 0 | NA | |
| 135 | hsa-miR-429 | TICAM2 | -1.4 | 7.0E-5 | 0.43 | 0.04519 | miRanda | -0.11 | 0.00034 | NA | |
| 136 | hsa-miR-107 | TLR4 | 0.24 | 0.01708 | -1.68 | 0 | miRanda | -0.31 | 0.00013 | NA | |
| 137 | hsa-miR-17-5p | TLR4 | 0.7 | 2.0E-5 | -1.68 | 0 | TargetScan | -0.32 | 0 | NA | |
| 138 | hsa-miR-21-5p | TLR4 | 1.51 | 0 | -1.68 | 0 | miRNAWalker2 validate | -0.45 | 0 | 27286259 | For in vivo relevance expression of TLR4 was correlated with miR-21 expression and ROS production in freshly isolated untreated primary human lung cancer cells |
| 139 | hsa-miR-331-5p | TLR4 | 0.21 | 0.12077 | -1.68 | 0 | MirTarget | -0.14 | 0.02553 | NA | |
| 140 | hsa-miR-421 | TLR4 | 0.94 | 0 | -1.68 | 0 | miRanda | -0.21 | 1.0E-5 | NA | |
| 141 | hsa-miR-221-3p | TNFSF10 | 1.12 | 0 | -0.72 | 5.0E-5 | miRNAWalker2 validate; miRTarBase | -0.28 | 0 | NA | |
| 142 | hsa-miR-222-3p | TNFSF10 | 1.09 | 0 | -0.72 | 5.0E-5 | miRNAWalker2 validate; miRTarBase | -0.26 | 0 | NA | |
| 143 | hsa-miR-361-5p | TNFSF10 | 0.23 | 0.00962 | -0.72 | 5.0E-5 | miRanda | -0.23 | 0.01907 | NA | |
| 144 | hsa-miR-98-5p | TNFSF10 | -0.05 | 0.71591 | -0.72 | 5.0E-5 | miRNAWalker2 validate | -0.19 | 0.00382 | NA | |
| 145 | hsa-miR-150-5p | VEGFA | -1.15 | 0 | 0.03 | 0.81383 | miRNAWalker2 validate; miRTarBase | -0.11 | 0 | NA | |
| 146 | hsa-miR-29b-2-5p | VEGFA | -0.22 | 0.08431 | 0.03 | 0.81383 | MirTarget | -0.13 | 0.00172 | NA | |
| 147 | hsa-miR-29b-3p | VEGFA | -0.35 | 0.01214 | 0.03 | 0.81383 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.13 | 0.00126 | 26155940; 22815235 | Moreover miR-29b inhibits angiogenesis by attenuating tube formation and the expression of VEGF and Ang-2 and stemness maintenance in GBM cells as demonstrated by decreasing neurosphere formation and cancer stem cell marker protein expression;Additionally for two genes that are deregulated in PCa heterogeneous nuclear ribonucleoprotein K hnRNP-K and vascular endothelial growth factor A VEGF-A we identified two regulatory miRNAs miR-205 and miR-29b |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | IMMUNE SYSTEM PROCESS | 18 | 1984 | 1.57e-12 | 7.303e-09 |
| 2 | REGULATION OF RESPONSE TO STRESS | 15 | 1468 | 6.75e-11 | 1.57e-07 |
| 3 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 9 | 321 | 2.298e-10 | 3.564e-07 |
| 4 | RESPONSE TO BIOTIC STIMULUS | 12 | 886 | 4.988e-10 | 5.802e-07 |
| 5 | RESPONSE TO CYTOKINE | 11 | 714 | 8.605e-10 | 8.008e-07 |
| 6 | REGULATION OF DEFENSE RESPONSE | 11 | 759 | 1.637e-09 | 9.994e-07 |
| 7 | RESPONSE TO EXTERNAL STIMULUS | 15 | 1821 | 1.4e-09 | 9.994e-07 |
| 8 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 15 | 1848 | 1.718e-09 | 9.994e-07 |
| 9 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 11 | 867 | 6.575e-09 | 3.399e-06 |
| 10 | REGULATION OF IMMUNE SYSTEM PROCESS | 13 | 1403 | 7.466e-09 | 3.474e-06 |
| 11 | REGULATION OF INNATE IMMUNE RESPONSE | 8 | 357 | 1.574e-08 | 6.657e-06 |
| 12 | DEFENSE RESPONSE | 12 | 1231 | 2.053e-08 | 6.823e-06 |
| 13 | RESPONSE TO BACTERIUM | 9 | 528 | 1.786e-08 | 6.823e-06 |
| 14 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 7 | 233 | 1.938e-08 | 6.823e-06 |
| 15 | POSITIVE REGULATION OF INTERFERON GAMMA PRODUCTION | 5 | 65 | 2.368e-08 | 7.345e-06 |
| 16 | REGULATION OF CYTOKINE PRODUCTION | 9 | 563 | 3.104e-08 | 8e-06 |
| 17 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 14 | 1929 | 3.439e-08 | 8e-06 |
| 18 | CELL DEATH | 11 | 1001 | 2.909e-08 | 8e-06 |
| 19 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 6 | 144 | 3.279e-08 | 8e-06 |
| 20 | POSITIVE REGULATION OF INTERLEUKIN 6 PRODUCTION | 5 | 68 | 2.98e-08 | 8e-06 |
| 21 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 6 | 163 | 6.865e-08 | 1.483e-05 |
| 22 | POSITIVE REGULATION OF INTERFERON BETA PRODUCTION | 4 | 30 | 7.046e-08 | 1.483e-05 |
| 23 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 12 | 1381 | 7.352e-08 | 1.483e-05 |
| 24 | IMMUNE RESPONSE | 11 | 1100 | 7.648e-08 | 1.483e-05 |
| 25 | REGULATION OF IMMUNE RESPONSE | 10 | 858 | 8.693e-08 | 1.618e-05 |
| 26 | RESPONSE TO LIPID | 10 | 888 | 1.199e-07 | 2.146e-05 |
| 27 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 13 | 1805 | 1.51e-07 | 2.603e-05 |
| 28 | REGULATION OF INTERFERON GAMMA PRODUCTION | 5 | 97 | 1.794e-07 | 2.981e-05 |
| 29 | ACTIVATION OF INNATE IMMUNE RESPONSE | 6 | 204 | 2.59e-07 | 4.018e-05 |
| 30 | REGULATION OF INTERLEUKIN 6 PRODUCTION | 5 | 104 | 2.543e-07 | 4.018e-05 |
| 31 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 5 | 109 | 3.216e-07 | 4.828e-05 |
| 32 | REGULATION OF INTERFERON BETA PRODUCTION | 4 | 44 | 3.445e-07 | 4.966e-05 |
| 33 | REGULATION OF TYPE I INTERFERON PRODUCTION | 5 | 111 | 3.522e-07 | 4.966e-05 |
| 34 | POSITIVE REGULATION OF DEFENSE RESPONSE | 7 | 364 | 4.052e-07 | 5.545e-05 |
| 35 | LEUKOCYTE CHEMOTAXIS | 5 | 117 | 4.579e-07 | 5.918e-05 |
| 36 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 7 | 370 | 4.524e-07 | 5.918e-05 |
| 37 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 12 | 1656 | 5.345e-07 | 6.554e-05 |
| 38 | POSITIVE REGULATION OF CHEMOKINE PRODUCTION | 4 | 49 | 5.353e-07 | 6.554e-05 |
| 39 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 6 | 246 | 7.767e-07 | 9.266e-05 |
| 40 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 11 | 1395 | 8.398e-07 | 9.769e-05 |
| 41 | POSITIVE REGULATION OF GENE EXPRESSION | 12 | 1733 | 8.723e-07 | 9.792e-05 |
| 42 | POSITIVE REGULATION OF CELL DEATH | 8 | 605 | 8.938e-07 | 9.792e-05 |
| 43 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 8 | 606 | 9.049e-07 | 9.792e-05 |
| 44 | DENDRITIC CELL CHEMOTAXIS | 3 | 16 | 1.214e-06 | 0.0001234 |
| 45 | POSITIVE REGULATION OF INTERFERON ALPHA PRODUCTION | 3 | 16 | 1.214e-06 | 0.0001234 |
| 46 | CELLULAR DEFENSE RESPONSE | 4 | 60 | 1.22e-06 | 0.0001234 |
| 47 | CYTOKINE MEDIATED SIGNALING PATHWAY | 7 | 452 | 1.726e-06 | 0.0001654 |
| 48 | REGULATION OF CHEMOKINE PRODUCTION | 4 | 65 | 1.685e-06 | 0.0001654 |
| 49 | INFLAMMATORY RESPONSE | 7 | 454 | 1.777e-06 | 0.0001654 |
| 50 | TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 3 | 18 | 1.766e-06 | 0.0001654 |
| 51 | CELLULAR RESPONSE TO LIPID | 7 | 457 | 1.857e-06 | 0.0001694 |
| 52 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 9 | 926 | 2.073e-06 | 0.000184 |
| 53 | REGULATION OF INTERFERON ALPHA PRODUCTION | 3 | 19 | 2.096e-06 | 0.000184 |
| 54 | CELL CHEMOTAXIS | 5 | 162 | 2.291e-06 | 0.0001903 |
| 55 | POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 4 | 70 | 2.272e-06 | 0.0001903 |
| 56 | POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 6 | 296 | 2.276e-06 | 0.0001903 |
| 57 | CHEMOKINE MEDIATED SIGNALING PATHWAY | 4 | 72 | 2.545e-06 | 0.0002077 |
| 58 | DENDRITIC CELL MIGRATION | 3 | 21 | 2.871e-06 | 0.0002155 |
| 59 | NECROPTOTIC PROCESS | 3 | 21 | 2.871e-06 | 0.0002155 |
| 60 | POSITIVE REGULATION OF NEUROBLAST PROLIFERATION | 3 | 21 | 2.871e-06 | 0.0002155 |
| 61 | INTRACELLULAR SIGNAL TRANSDUCTION | 11 | 1572 | 2.734e-06 | 0.0002155 |
| 62 | REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 4 | 73 | 2.69e-06 | 0.0002155 |
| 63 | REGULATION OF HEMOPOIESIS | 6 | 314 | 3.201e-06 | 0.0002364 |
| 64 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 11 | 1618 | 3.625e-06 | 0.0002636 |
| 65 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 9 | 1004 | 4.032e-06 | 0.0002886 |
| 66 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 5 | 197 | 5.965e-06 | 0.0004205 |
| 67 | NECROTIC CELL DEATH | 3 | 28 | 7.028e-06 | 0.0004769 |
| 68 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 8 | 799 | 7.072e-06 | 0.0004769 |
| 69 | REGULATION OF NEUROBLAST PROLIFERATION | 3 | 28 | 7.028e-06 | 0.0004769 |
| 70 | POSITIVE REGULATION OF IMMUNE RESPONSE | 7 | 563 | 7.341e-06 | 0.000488 |
| 71 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 6 | 365 | 7.59e-06 | 0.0004974 |
| 72 | CELL ACTIVATION | 7 | 568 | 7.777e-06 | 0.0005026 |
| 73 | POSITIVE REGULATION OF CELL PROLIFERATION | 8 | 814 | 8.106e-06 | 0.0005167 |
| 74 | MYELOID LEUKOCYTE ACTIVATION | 4 | 98 | 8.724e-06 | 0.0005485 |
| 75 | MACROPHAGE ACTIVATION | 3 | 31 | 9.617e-06 | 0.0005966 |
| 76 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 4 | 103 | 1.063e-05 | 0.0006507 |
| 77 | POSITIVE REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 3 | 33 | 1.165e-05 | 0.0006951 |
| 78 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 3 | 33 | 1.165e-05 | 0.0006951 |
| 79 | REGULATION OF CELL DEATH | 10 | 1472 | 1.194e-05 | 0.0007034 |
| 80 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 5 | 232 | 1.319e-05 | 0.0007629 |
| 81 | INNATE IMMUNE RESPONSE | 7 | 619 | 1.361e-05 | 0.0007629 |
| 82 | REGULATION OF CELL DIFFERENTIATION | 10 | 1492 | 1.345e-05 | 0.0007629 |
| 83 | NEGATIVE REGULATION OF CELL DEATH | 8 | 872 | 1.34e-05 | 0.0007629 |
| 84 | POSITIVE REGULATION OF INTERLEUKIN 1 PRODUCTION | 3 | 36 | 1.521e-05 | 0.0008424 |
| 85 | LEUKOCYTE ACTIVATION | 6 | 414 | 1.553e-05 | 0.0008503 |
| 86 | POSITIVE REGULATION OF CELL COMMUNICATION | 10 | 1532 | 1.697e-05 | 0.0009183 |
| 87 | ACTIVATION OF IMMUNE RESPONSE | 6 | 427 | 1.85e-05 | 0.0009894 |
| 88 | LEUKOCYTE MIGRATION | 5 | 259 | 2.24e-05 | 0.001185 |
| 89 | POSITIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 3 | 42 | 2.432e-05 | 0.001271 |
| 90 | REGULATION OF PROTEIN LOCALIZATION | 8 | 950 | 2.491e-05 | 0.001288 |
| 91 | REGULATION OF CELLULAR RESPONSE TO STRESS | 7 | 691 | 2.767e-05 | 0.001415 |
| 92 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 4 | 133 | 2.913e-05 | 0.001473 |
| 93 | REGULATION OF MULTI ORGANISM PROCESS | 6 | 470 | 3.174e-05 | 0.001576 |
| 94 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 8 | 983 | 3.183e-05 | 0.001576 |
| 95 | POSITIVE REGULATION OF RESPONSE TO EXTRACELLULAR STIMULUS | 3 | 48 | 3.644e-05 | 0.001766 |
| 96 | POSITIVE REGULATION OF RESPONSE TO NUTRIENT LEVELS | 3 | 48 | 3.644e-05 | 0.001766 |
| 97 | APOPTOTIC SIGNALING PATHWAY | 5 | 289 | 3.785e-05 | 0.001816 |
| 98 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 9 | 1360 | 4.623e-05 | 0.002195 |
| 99 | DEFENSE RESPONSE TO OTHER ORGANISM | 6 | 505 | 4.741e-05 | 0.002228 |
| 100 | REGULATION OF JNK CASCADE | 4 | 159 | 5.853e-05 | 0.002696 |
| 101 | OUTFLOW TRACT MORPHOGENESIS | 3 | 56 | 5.799e-05 | 0.002696 |
| 102 | POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 3 | 57 | 6.115e-05 | 0.00279 |
| 103 | POSITIVE REGULATION OF HEMOPOIESIS | 4 | 163 | 6.447e-05 | 0.002884 |
| 104 | REGULATION OF INTERLEUKIN 1 PRODUCTION | 3 | 58 | 6.443e-05 | 0.002884 |
| 105 | REGULATION OF EPITHELIAL CELL MIGRATION | 4 | 166 | 6.92e-05 | 0.003064 |
| 106 | REGULATION OF TRANSPORT | 10 | 1804 | 6.981e-05 | 0.003064 |
| 107 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 7 | 801 | 7.081e-05 | 0.003079 |
| 108 | POSITIVE REGULATION OF STEM CELL PROLIFERATION | 3 | 61 | 7.495e-05 | 0.003229 |
| 109 | POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 4 | 172 | 7.943e-05 | 0.003391 |
| 110 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 7 | 823 | 8.399e-05 | 0.003553 |
| 111 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 4 | 179 | 9.27e-05 | 0.003886 |
| 112 | POSITIVE REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 2 | 11 | 9.581e-05 | 0.00398 |
| 113 | REGULATION OF CELL PROLIFERATION | 9 | 1496 | 9.729e-05 | 0.004006 |
| 114 | REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 3 | 67 | 9.922e-05 | 0.00405 |
| 115 | REGULATION OF MYELOID CELL DIFFERENTIATION | 4 | 183 | 0.000101 | 0.004085 |
| 116 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 68 | 0.0001037 | 0.00416 |
| 117 | RESPONSE TO NITROGEN COMPOUND | 7 | 859 | 0.0001099 | 0.004369 |
| 118 | I KAPPAB KINASE NF KAPPAB SIGNALING | 3 | 70 | 0.0001131 | 0.004459 |
| 119 | MICROGLIAL CELL ACTIVATION | 2 | 12 | 0.0001149 | 0.004492 |
| 120 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 7 | 876 | 0.0001242 | 0.004789 |
| 121 | NEGATIVE REGULATION OF CELL COMMUNICATION | 8 | 1192 | 0.0001245 | 0.004789 |
| 122 | POSITIVE REGULATION OF AUTOPHAGY | 3 | 75 | 0.0001389 | 0.005296 |
| 123 | REGULATION OF PROTEIN SECRETION | 5 | 389 | 0.0001539 | 0.005821 |
| 124 | REGULATION OF SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 4 | 205 | 0.0001564 | 0.005867 |
| 125 | POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 2 | 14 | 0.0001581 | 0.005886 |
| 126 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 7 | 917 | 0.000165 | 0.006093 |
| 127 | POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 3 | 81 | 0.0001745 | 0.0063 |
| 128 | REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 4 | 211 | 0.0001747 | 0.0063 |
| 129 | NEGATIVE REGULATION OF CYTOKINE PRODUCTION | 4 | 211 | 0.0001747 | 0.0063 |
| 130 | POSITIVE REGULATION OF T HELPER 1 TYPE IMMUNE RESPONSE | 2 | 15 | 0.0001823 | 0.006525 |
| 131 | POSITIVE REGULATION OF TRANSPORT | 7 | 936 | 0.0001873 | 0.006654 |
| 132 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 85 | 0.0002013 | 0.007042 |
| 133 | REGULATION OF CELLULAR LOCALIZATION | 8 | 1277 | 0.0002008 | 0.007042 |
| 134 | REGULATION OF MAPK CASCADE | 6 | 660 | 0.0002065 | 0.007079 |
| 135 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 6 | 662 | 0.0002099 | 0.007079 |
| 136 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 16 | 0.0002082 | 0.007079 |
| 137 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 6 | 662 | 0.0002099 | 0.007079 |
| 138 | MONOCYTE DIFFERENTIATION | 2 | 16 | 0.0002082 | 0.007079 |
| 139 | REGULATION OF STEM CELL PROLIFERATION | 3 | 88 | 0.000223 | 0.007466 |
| 140 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 9 | 1672 | 0.0002282 | 0.007583 |
| 141 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 4 | 228 | 0.0002349 | 0.007617 |
| 142 | MAMMARY GLAND ALVEOLUS DEVELOPMENT | 2 | 17 | 0.0002357 | 0.007617 |
| 143 | MAMMARY GLAND LOBULE DEVELOPMENT | 2 | 17 | 0.0002357 | 0.007617 |
| 144 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 2 | 17 | 0.0002357 | 0.007617 |
| 145 | REGULATION OF VASCULATURE DEVELOPMENT | 4 | 233 | 0.0002552 | 0.008189 |
| 146 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 5 | 437 | 0.0002642 | 0.008387 |
| 147 | REGULATION OF TUMOR NECROSIS FACTOR BIOSYNTHETIC PROCESS | 2 | 18 | 0.000265 | 0.008387 |
| 148 | NEGATIVE REGULATION OF GROWTH | 4 | 236 | 0.000268 | 0.008424 |
| 149 | REGULATION OF PROTEIN MODIFICATION PROCESS | 9 | 1710 | 0.0002704 | 0.008445 |
| 150 | REGULATION OF ERK1 AND ERK2 CASCADE | 4 | 238 | 0.0002767 | 0.008583 |
| 151 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 3 | 95 | 0.0002796 | 0.008615 |
| 152 | REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 19 | 0.0002959 | 0.008999 |
| 153 | POSITIVE REGULATION OF ALPHA BETA T CELL PROLIFERATION | 2 | 19 | 0.0002959 | 0.008999 |
| 154 | REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 98 | 0.0003064 | 0.009257 |
| 155 | MYELOID LEUKOCYTE MIGRATION | 3 | 99 | 0.0003157 | 0.009476 |
| 156 | RESPONSE TO VIRUS | 4 | 247 | 0.0003186 | 0.009504 |
| 157 | EMBRYONIC HEMOPOIESIS | 2 | 20 | 0.0003285 | 0.009736 |
| 158 | REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 3 | 101 | 0.0003348 | 0.009859 |
| 159 | COGNITION | 4 | 251 | 0.0003387 | 0.009911 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CYTOKINE BINDING | 6 | 92 | 2.199e-09 | 1.021e-06 |
| 2 | CYTOKINE RECEPTOR ACTIVITY | 6 | 89 | 1.797e-09 | 1.021e-06 |
| 3 | CHEMOKINE BINDING | 4 | 21 | 1.552e-08 | 4.805e-06 |
| 4 | G PROTEIN COUPLED CHEMOATTRACTANT RECEPTOR ACTIVITY | 4 | 25 | 3.267e-08 | 7.588e-06 |
| 5 | SIGNAL TRANSDUCER ACTIVITY | 11 | 1731 | 6.986e-06 | 0.001298 |
| 6 | PEPTIDE RECEPTOR ACTIVITY | 4 | 133 | 2.913e-05 | 0.00451 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | Necroptosis_hsa04217 | 7 | 164 | 1.696e-09 | 4.598e-08 | |
| 2 | Cytokine_cytokine_receptor_interaction_hsa04060 | 8 | 270 | 1.768e-09 | 4.598e-08 | |
| 3 | HIF_1_signaling_pathway_hsa04066 | 5 | 100 | 2.09e-07 | 3.623e-06 | |
| 4 | Mitophagy_animal_hsa04137 | 3 | 65 | 9.064e-05 | 0.001178 | |
| 5 | NF_kappa_B_signaling_pathway_hsa04064 | 3 | 95 | 0.0002796 | 0.002908 | |
| 6 | PI3K_Akt_signaling_pathway_hsa04151 | 4 | 352 | 0.001202 | 0.01042 | |
| 7 | cAMP_signaling_pathway_hsa04024 | 3 | 198 | 0.002346 | 0.01743 | |
| 8 | TNF_signaling_pathway_hsa04668 | 2 | 108 | 0.009286 | 0.06036 | |
| 9 | AMPK_signaling_pathway_hsa04152 | 2 | 121 | 0.01154 | 0.06669 | |
| 10 | Apoptosis_hsa04210 | 2 | 138 | 0.01482 | 0.07144 | |
| 11 | Phospholipase_D_signaling_pathway_hsa04072 | 2 | 146 | 0.01649 | 0.07144 | |
| 12 | Wnt_signaling_pathway_hsa04310 | 2 | 146 | 0.01649 | 0.07144 | |
| 13 | Jak_STAT_signaling_pathway_hsa04630 | 2 | 162 | 0.02004 | 0.08018 | |
| 14 | Focal_adhesion_hsa04510 | 2 | 199 | 0.02937 | 0.1085 | |
| 15 | Rap1_signaling_pathway_hsa04015 | 2 | 206 | 0.0313 | 0.1085 | |
| 16 | Endocytosis_hsa04144 | 2 | 244 | 0.0426 | 0.1384 | |
| 17 | MAPK_signaling_pathway_hsa04010 | 2 | 295 | 0.05976 | 0.1779 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RP1-27K12.2 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-320a;hsa-miR-338-3p;hsa-miR-338-5p;hsa-miR-375;hsa-miR-93-5p | 10 | RNASEL | Sponge network | -0.954 | 0.22875 | -0.298 | 0.08846 | 0.394 |
| 2 | RP11-747H7.3 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p;hsa-miR-34a-5p;hsa-miR-374a-5p;hsa-miR-374b-5p;hsa-miR-664a-3p | 14 | MGAT4A | Sponge network | 0.351 | 0.40524 | 0.104 | 0.34719 | 0.353 |
| 3 | AC025335.1 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p | 11 | MGAT4A | Sponge network | 1.297 | 0 | 0.104 | 0.34719 | 0.327 |
| 4 | FAM225B | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p | 11 | MGAT4A | Sponge network | 0.684 | 0.04717 | 0.104 | 0.34719 | 0.31 |
| 5 | RP11-479G22.8 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-374b-5p | 10 | MGAT4A | Sponge network | 1.511 | 0 | 0.104 | 0.34719 | 0.305 |
| 6 | AC005562.1 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p | 10 | MGAT4A | Sponge network | 1.127 | 0 | 0.104 | 0.34719 | 0.301 |
| 7 | RP11-159D12.2 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p | 10 | MGAT4A | Sponge network | 1.574 | 0 | 0.104 | 0.34719 | 0.294 |
| 8 | TUG1 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p | 10 | MGAT4A | Sponge network | 0.972 | 0 | 0.104 | 0.34719 | 0.287 |
| 9 | CASC2 | hsa-miR-103a-3p;hsa-miR-107;hsa-miR-148b-3p;hsa-miR-17-5p;hsa-miR-193a-3p;hsa-miR-20a-5p;hsa-miR-338-3p;hsa-miR-338-5p;hsa-miR-421;hsa-miR-93-5p | 10 | RNASEL | Sponge network | -0.596 | 0.00187 | -0.298 | 0.08846 | 0.276 |
| 10 | MAGI2-AS3 |
hsa-miR-103a-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-148b-3p;hsa-miR-17-5p;hsa-miR-193a-3p;hsa-miR-20a-5p;hsa-miR-320b;hsa-miR-324-5p;hsa-miR-330-5p;hsa-miR-421;hsa-miR-589-3p;hsa-miR-93-5p | 14 | RNASEL | Sponge network | -1.801 | 0 | -0.298 | 0.08846 | 0.269 |
| 11 | RP11-89K21.1 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p;hsa-miR-374a-5p;hsa-miR-374b-5p | 13 | MGAT4A | Sponge network | 4.915 | 0 | 0.104 | 0.34719 | 0.267 |
| 12 | VAC14-AS1 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-15a-5p;hsa-miR-23b-3p;hsa-miR-374a-5p;hsa-miR-374b-5p | 11 | MGAT4A | Sponge network | 2.836 | 5.0E-5 | 0.104 | 0.34719 | 0.259 |
| 13 | LINC00342 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-126-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p | 11 | MGAT4A | Sponge network | 1.503 | 0 | 0.104 | 0.34719 | 0.258 |
| 14 | MAGI2-AS3 |
hsa-miR-15b-3p;hsa-miR-188-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-301a-3p;hsa-miR-30d-5p;hsa-miR-362-5p;hsa-miR-454-3p;hsa-miR-500a-5p;hsa-miR-501-5p | 10 | CYLD | Sponge network | -1.801 | 0 | -0.423 | 0 | 0.255 |
| 15 | SMIM2-AS1 | hsa-miR-103a-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-148b-3p;hsa-miR-17-5p;hsa-miR-193a-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-324-5p;hsa-miR-330-5p;hsa-miR-589-3p | 11 | RNASEL | Sponge network | -0.66 | 0.00587 | -0.298 | 0.08846 | 0.255 |
| 16 | LINC00654 | hsa-let-7c-5p;hsa-miR-101-3p;hsa-miR-107;hsa-miR-125b-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-194-5p;hsa-miR-23b-3p;hsa-miR-30b-3p;hsa-miR-30d-3p | 11 | MGAT4A | Sponge network | 0.697 | 0.02064 | 0.104 | 0.34719 | 0.252 |